Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Percutaneous ethanol injection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Percutaneous ethanol injection. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-011276-29 Sponsor Protocol Number: L00122 GI 201 (ORF) Start Date*: 2009-08-21
    Sponsor Name:ORFAGEN
    Full Title: Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with c...
    Medical condition: patients with congenital venous malformations (CVM)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001770-40 Sponsor Protocol Number: 11546 Start Date*: 2005-06-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma.
    Medical condition: advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10049010 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000311-25 Sponsor Protocol Number: BAY86-9766/16553 Start Date*: 2013-10-17
    Sponsor Name:Bayer Healthcare AG
    Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)
    Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) AT (Completed) GB (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000241-39 Sponsor Protocol Number: BAY86-9766/16728 Start Date*: 2013-07-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato...
    Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000566-23 Sponsor Protocol Number: GK-001-01 Start Date*: 2008-08-25
    Sponsor Name:GeneCare Research Institute Co., Ltd.
    Full Title: A randomized phase 2 double-blind, placebo-controlled study of GK-001 in hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment Estudio aleatorizado de ...
    Medical condition: hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment carcinoma hepatocelular (CHC) en pacientes con hepatitis C crónica tras tratamiento curativo para...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001773-26 Sponsor Protocol Number: 100554 Start Date*: 2005-05-03
    Sponsor Name:Bayer HealthCare AG, D-51368 Leverkusen Germany
    Full Title: A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10049010 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-007629-32 Sponsor Protocol Number: TAC101-202 Start Date*: 2009-02-19
    Sponsor Name:Taiho Pharma USA, Inc.
    Full Title: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SO...
    Medical condition: Advanced Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003649-14 Sponsor Protocol Number: Bay73-4506/15982 Start Date*: 2013-01-30
    Sponsor Name:Bayer AG
    Full Title: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012570-13 Sponsor Protocol Number: BAY73-4506/14596 Start Date*: 2009-08-25
    Sponsor Name:Bayer HealthCare AG, D51368 Leverkusen
    Full Title: An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC)
    Medical condition: Hepatocellular carcinoma, in patients who have failed (experienced radiological progression) previous treatment cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003533-24 Sponsor Protocol Number: CA182033 Start Date*: 2009-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogeneti...
    Medical condition: advanced hepatocellular carcinoma /////////// Carcinoma Hepatocelular avanzado
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-011904-47 Sponsor Protocol Number: SoraDox2009 Start Date*: 2010-11-18
    Sponsor Name:Ethik-Kommission der Medizinischen Fakultät der Martin-Luther-Universität Halle Wittenberg
    Full Title: Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial
    Medical condition: Advanced hepatocellular carcinoma (HCC) stage C (or better) according to BCLC classification restricted to Child-Pugh class A/B (5-7 points).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001973-66 Sponsor Protocol Number: ML42243 Start Date*: 2020-07-16
    Sponsor Name:ROCHE SPA
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT...
    Medical condition: Unresectable hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006021-14 Sponsor Protocol Number: BAY43-9006/12917 Start Date*: 2009-07-01
    Sponsor Name:Bayer AG
    Full Title: A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)
    Medical condition: To evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotibib 150 mg once a day in subjects with unresectable advanced or metastatic Child-Pugh A HCC.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    19.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006637-14 Sponsor Protocol Number: A6181170 Start Date*: 2008-09-01
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017
    Full Title: A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SUNITINIB MALATE VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003308-10 Sponsor Protocol Number: ARQ197-A-U303 Start Date*: 2012-12-20
    Sponsor Name:DAIICHI SANKIO DEVELOPMENT LIMITED
    Full Title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Medical condition: MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) NL (Completed) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001012-68 Sponsor Protocol Number: CA182-006 Start Date*: 2007-04-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients...
    Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002041-36 Sponsor Protocol Number: POLARIS2009-001 Start Date*: 2011-11-15
    Sponsor Name:Polaris Group
    Full Title: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Fai...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000144-18 Sponsor Protocol Number: CDKO-125a-010 Start Date*: 2017-08-01
    Sponsor Name:Tiziana Life Sciences Plc
    Full Title: Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma
    Medical condition: Uunresectable or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007155-27 Sponsor Protocol Number: ARQ197-215 Start Date*: 2009-10-22
    Sponsor Name:ArQule, Inc.
    Full Title: A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
    Medical condition: Unresectable hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005084-34 Sponsor Protocol Number: CA182034 Start Date*: 2009-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019829 Hepatocellular carcinoma recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SE (Completed) FR (Completed) GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:15:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA